Invesco’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$259M Buy
4,012,494
+364,431
+10% +$25.7M 0.03% 601
2025
Q4
$246M Buy
3,648,063
+402,293
+12% +$27.1M 0.02% 599
2025
Q3
$238M Sell
3,245,770
-220,119
-6% -$14.6M 0.04% 594
2025
Q2
$180M Sell
3,465,889
-428,408
-11% -$24.4M 0.03% 674
2025
Q1
$248M Buy
3,894,297
+1,519,875
+64% +$88.3M 0.05% 514
2024
Q4
$114M Buy
2,374,422
+462,762
+24% +$23.7M 0.02% 778
2024
Q3
$109M Sell
1,911,660
-312,278
-14% -$17.9M 0.02% 772
2024
Q2
$116M Buy
2,223,938
+135,528
+6% +$5.94M 0.02% 732
2024
Q1
$85M Buy
2,088,410
+57,776
+3% +$2.17M 0.02% 831
2023
Q4
$75.1M Buy
2,030,634
+13,612
+0.7% +$513K 0.02% 844
2023
Q3
$77.1M Sell
2,017,022
-459,123
-19% -$18.8M 0.02% 805
2023
Q2
$89.3M Sell
2,476,145
-1,015,032
-29% -$34.6M 0.02% 755
2023
Q1
$133M Sell
3,491,177
-2,514,274
-42% -$118M 0.04% 605
2022
Q4
$342M Buy
6,005,451
+366,954
+7% +$18.8M 0.1% 275
2022
Q3
$223M Buy
5,638,497
+67,802
+1% +$3M 0.07% 377
2022
Q2
$245M Buy
5,570,695
+249,572
+5% +$10.8M 0.07% 362
2022
Q1
$212M Sell
5,321,123
-185,110
-3% -$6.59M 0.05% 472
2021
Q4
$221M Buy
5,506,233
+176,888
+3% +$6.6M 0.05% 482
2021
Q3
$217M Sell
5,329,345
-322,277
-6% -$13.5M 0.05% 459
2021
Q2
$257M Buy
5,651,622
+129,888
+2% +$5.75M 0.06% 395
2021
Q1
$230M Buy
5,521,734
+189,126
+4% +$8.63M 0.06% 408
2020
Q4
$228M Buy
5,332,608
+1,086,911
+26% +$39.1M 0.07% 376
2020
Q3
$112M Buy
4,245,697
+563,416
+15% +$15.7M 0.04% 597
2020
Q2
$98.7M Buy
3,682,281
+4,349
+0.1% +$98.1K 0.04% 596
2020
Q1
$66.2M Sell
3,677,932
-1,050,885
-22% -$19.9M 0.03% 671
2019
Q4
$83.8M Sell
4,728,817
-537,977
-10% -$9.32M 0.03% 750
2019
Q3
$81.7M Sell
5,266,794
-120,615
-2% -$1.99M 0.02% 745
2019
Q2
$92.6M Buy
5,387,409
+1,183,551
+28% +$19.1M 0.02% 719
2019
Q1
$67.7M Sell
4,203,858
-10,256
-0.2% -$166K 0.02% 695
2018
Q4
$61.7M Buy
4,214,114
+34,661
+0.8% +$553K 0.02% 662
2018
Q3
$75.9M Buy
4,179,453
+113,537
+3% +$1.99M 0.02% 674
2018
Q2
$68.6M Sell
4,065,916
-161,566
-4% -$3.05M 0.02% 701
2018
Q1
$82.8M Sell
4,227,482
-13,130
-0.3% -$254K 0.03% 541
2017
Q4
$85.9M Sell
4,240,612
-185,614
-4% -$3.41M 0.03% 552
2017
Q3
$76.9M Sell
4,426,226
-16,074
-0.4% -$218K 0.03% 596
2017
Q2
$57M Sell
4,442,300
-42,311
-0.9% -$565K 0.02% 716
2017
Q1
$58.1M Buy
4,484,611
+2,146,872
+92% +$27.1M 0.02% 711
2016
Q4
$23.1M Buy
2,337,739
+526,835
+29% +$5.77M 0.01% 1100
2016
Q3
$21.9M Buy
1,810,904
+17,370
+1% +$178K 0.01% 1117
2016
Q2
$15.5M Sell
1,793,534
-929,929
-34% -$9.18M 0.01% 1246
2016
Q1
$25.8M Buy
2,723,463
+331,990
+14% +$3.12M 0.01% 1027
2015
Q4
$41.4M Sell
2,391,473
-70,363
-3% -$1.12M 0.02% 845
2015
Q3
$33.1M Buy
2,461,836
+1,359,560
+123% +$27.3M 0.01% 930
2015
Q2
$24.9M Buy
+1,102,276
New +$19.4M 0.01% 1118
2014
Q1
Sell
-6,040
Closed -$91K 4149
2013
Q4
$91K Buy
+6,040
New +$77.7K ﹤0.01% 4036

Other funds holding HALO

Invesco's HALO Position: Q1 2026 in Review

Invesco increased its Halozyme (HALO) stake by 10% in Q1 2026, buying an estimated $25.7M and bringing the position to 4,012,494 shares worth $259M. The position accounts for 0.03% of the portfolio, ranked #601.

Invesco first reported a position in HALO in Q4 2013 and has held it in 45 quarters since. The position peaked at $342M in Q4 2022. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Invesco held 4,012,494 shares of Halozyme worth $259M as of Q1 2026.
  • Invesco bought 364,431 Halozyme shares in Q1 2026, an estimated $25.7M.
  • Halozyme made up 0.03% of Invesco's portfolio in Q1 2026, its #601 holding.
  • Invesco first reported a position in Halozyme in Q4 2013 and has held it in 45 quarters since.
  • Invesco's Halozyme position peaked at $342M in Q4 2022.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.